P. Celigny, M. Bellei, and L. Marcheselli, Watchful Waiting in Low???Tumor Burden Follicular Lymphoma in the Rituximab Era: Results of an F2-Study Database, of statins or detrimentally effected by the potential adverse action of statins on anti CD20 binding. REFERENCES 1. Solal, pp.3848-53, 20122.
DOI : 10.1200/JCO.2010.33.4474

S. Horning, J. Unger, and L. Rimsza, Natural history of and therapy for the indolent non-Hodgkin's lymphomas Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016, Semin Oncol J Clin Oncol, vol.20, issue.31, pp.75-88314, 1993.

C. Gallagher, W. Gregory, and A. Jones, Follicular lymphoma: prognostic factors for response and survival., Journal of Clinical Oncology, vol.4, issue.10, pp.1470-803052, 1986.
DOI : 10.1200/JCO.1986.4.10.1470

M. Herold, A. Haas, and S. Srock, Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study, Journal of Clinical Oncology, vol.25, issue.15, pp.1986-92, 2007.
DOI : 10.1200/JCO.2006.06.4618

W. Hiddemann, M. Kneba, and M. Dreyling, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group, Blood, vol.106, issue.12, pp.3725-3757, 2005.
DOI : 10.1182/blood-2005-01-0016

Q. Liu, L. Fayad, and F. Cabanillas, Improvement of Overall and Failure-Free Survival in Stage IV Follicular Lymphoma: 25 Years of Treatment Experience at The University of Texas M.D. Anderson Cancer Center, Journal of Clinical Oncology, vol.24, issue.10, pp.1582-94824, 2006.
DOI : 10.1200/JCO.2005.03.3696

W. Swenson, J. Wooldridge, and C. Lynch, Improved Survival of Follicular Lymphoma Patients in the United States, Journal of Clinical Oncology, vol.23, issue.22, pp.5019-5045, 200511.
DOI : 10.1200/JCO.2005.04.503

H. Hochster, E. Weller, and R. Gascoyne, Maintenance Rituximab After Cyclophosphamide, Vincristine, and Prednisone Prolongs Progression-Free Survival in Advanced Indolent Lymphoma: Results of the Randomized Phase III ECOG1496 Study, Journal of Clinical Oncology, vol.27, issue.10, pp.1607-1621, 200912.
DOI : 10.1200/JCO.2008.17.1561

E. Bachy, R. Houot, and F. Morschhauser, Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma, Haematologica, vol.98, issue.7, pp.1107-1121, 201313.
DOI : 10.3324/haematol.2012.082412
URL : https://hal.archives-ouvertes.fr/hal-00933219

E. Bachy, P. Brice, and R. Delarue, Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival???A Study From the Groupe d'Etude des Lymphomes de l'Adulte, Journal of Clinical Oncology, vol.28, issue.5, pp.822-831, 201014.
DOI : 10.1200/JCO.2009.22.7819
URL : https://hal.archives-ouvertes.fr/hal-00453229

A. Gopal, B. Kahl, and S. De-vos, PI3Kdelta Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma, N Engl J Med, 201415.

J. Radford, A. Davies, and G. Cartron, Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000), Blood, vol.122, issue.7, 21000.
DOI : 10.1182/blood-2013-01-481341

S. Nielsen, B. Nordestgaard, and S. Bojesen, Statin Use and Reduced Cancer-Related Mortality, New England Journal of Medicine, vol.367, issue.19, pp.1792-8022, 2012.
DOI : 10.1056/NEJMoa1201735

O. Yu, M. Eberg, and S. Benayoun, Use of statins and the risk of death in patients with prostate cancer Statins impair antitumor effects of rituximab by inducing conformational changes of CD20 Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of complementdependent cytotoxicity, J Clin Oncol PLoS Med J Biol Chem, vol.32, issue.287, pp.5-11, 200820.

G. Nowakowski, M. Maurer, and T. Habermann, Statin Use and Prognosis in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in the Rituximab Era, Journal of Clinical Oncology, vol.28, issue.3
DOI : 10.1200/JCO.2009.23.4245

P. Samaras, H. Heider, and S. Haile, Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP, Annals of Hematology, vol.366, issue.8, pp.412-7783, 201022.
DOI : 10.1007/s00277-010-0926-0

Y. Chae, L. Trinh, and P. Jain, Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia, Blood, vol.123, issue.9, pp.1424-642, 201125.
DOI : 10.1182/blood-2013-07-517102

B. Cheson, B. Pfistner, and M. Juweid, Revised Response Criteria for Malignant Lymphoma, Journal of Clinical Oncology, vol.25, issue.5, pp.579-86, 200726.
DOI : 10.1200/JCO.2006.09.2403

M. Jakobisiak and J. Golab, Potential antitumor effects of statins (Review), International Journal of Oncology, vol.23, pp.1055-69, 2003.
DOI : 10.3892/ijo.23.4.1055